WeHealth by Servier and DEEPLINK MEDICAL sign a partnership to develop a new e-health solution
A technological breakthrough for patients with solid tumors
Paris, 13 March 2018 – WeHealth by Servier, the Servier Group’s e-Health department, and DEEPLINK MEDICAL signed a partnership to develop an e-Health solution designed to improve the monitoring of patients with solid tumors.
Medical imaging is fundamental to manage patients with solid tumors allowing to better assess the efficacy of a cancer therapy. It is mainly based on the morphological assessment of tumors (size, density, etc.) which can be estimated by measuring evaluation criteria (e.g. RECIST: Response Evaluation Criteria in Solid Tumors). These criteria, defined by WHO, are essential to assessing new cancer drugs in clinical trials. While oncologists and radiologists agree on the importance of monitoring these criteria and the need to include them in their daily practice, they are also vocal about the time and energy involved in collecting and assessing these criteria which make the assessment and monitoring process of tumor response to treatment long and complex.
It is to solve this problem that WeHealth by Servier and DEEPLINK MEDICAL, a start-up from Lyon, have formed a partnership to develop innovative data monitoring and sharing software to facilitate communication about patients’ medical records among healthcare professionals. Its functions enable the prescription, collection, analysis and monitoring of complex radiological data to be standardized and made accessible, in real time, to the medical practitioners concerned. The software will ensure data safety and transparency throughout the process.
This solution should thus facilitate communication between all the practitioners involved in medical supervision and help to improve the support of patients with solid tumors.
“WeHealth by Servier is investing in the design of software to assess patient response to therapy which could considerably optimise the therapeutic monitoring of patients with solid tumors”, declared Dr David Guez, director of WeHealth by Servier. “The first e-health tool dedicated to oncology conducted jointly by Servier, it showcases the Servier Group’s commitment to offering innovative, connected solutions, covering a complete range of therapeutic needs, to provide patients with better support in monitoring their illness.”
The agreement between WeHealth by Servier and DEEPLINK MEDICAL concerns an exclusive world distribution license outside France (including Monaco and France’s overseas possessions and territories).
“This partnership is an important accelerator for our company. The combination of a major group, such as Servier, with the agility of our structure, provides a unique opportunity to target wide-reaching distribution of the tool from the outset. The agreement also means that we can envisage rapid roll-out of this innovative solution on the international market, to the benefit of healthcare professionals and therefore, of their patients.” Dr Charles Journe, CEO of DEEPLINK MEDICAL
In March 2018, this solution entered the test phase at the Leon-Berard Cancer Centre for Lyon and Rhône-Alpes (France) for a period of 6 months. Its launch on the international market is scheduled for early 2019.
About WeHealth by Servier
WeHealth by Servier is the Group’s exciting new e-health brand. Its goal is to deliver an effective response to emerging healthcare market demand for e-health or connected health, with an approach centered on the patient.
WeHealth by Servier is driven by the spirit of entrepreneurship and intends to invest in innovations created in partnership with startups worldwide.
More information: www.wehealthbyservier.com
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,600 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs.
Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are nine molecular entities in clinical development in this area, targeting gastric and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune, cellular and targeted therapies, to deliver life-changing medicines to patients.
More information: www.servier.com
Sonia MARQUES : firstname.lastname@example.org – Tél. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Karine BOUSSEAU : email@example.com – Tél. +33 (0)1 55 72 60 37
About DEEPLINK MEDICAL
DEEPLINK MEDICAL is a Lyon-based company that publishes digital solutions for the innovation and optimization of healthcare provided by and for physicians.
In addition to the use of digital solutions for new medical uses, DEEPLINK MEDICAL, which is brimming with research and development ideas, is an accelerator of organizational innovation in healthcare.
This dynamic structure is driven by the alchemy of 3 complementary skills: medical, technical and organisational.
DEEPLINK MEDICAL’s innovative telemedicine solutions are now used in 40 healthcare centers in France.
For more information, click on http://deeplink-medical.com/
Find Deeplink Medical on our social media:
 Solid tumors: solid cancer tumors refer to the abnormal multiplication of cells in “solid” organs such as the breast or prostate, as opposed to leukemia, a type of cancer that affects the blood and bone marrow.
 WHO: World Health Organization
 according to a market survey conducted by the Research Partnership Ltd in February 2018 in Europe and the US on a sample of 75 healthcare professionals